In this study, researchers analyzed dermal papilla cells from cashmere goats and identified 3,857 differentially expressed genes associated with hair growth phases, follicle types, and sex, providing a foundational resource for future efforts to improve cashmere quality and yield.
This study reported that male military personnel with pneumonia experienced accelerated hair transition to the telogen phase, particularly among smokers and those with androgenic alopecia, indicating potential areas for targeted interventions.
November 2013 in “Institutional Repositories DataBase (IRDB)”
In this study, γ-ray exposure in mice decreased hair follicle density and pigmentation, suggesting damage to stem cells affecting hair follicle regeneration.
52 citations
,
January 2003 in “Journal of Investigative Dermatology”
This study found that thrombospondin-1 plays a critical role in hair follicle cycle regulation, with deficiency prolonging follicle growth and overexpression delaying it through antiangiogenic effects.
PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.
A 34-year-old woman is seeking effective hair concealers for thinning hair, having tried various medications like spironolactone and oral minoxidil without success. Recommendations include Boldify hairline powder and products like Hairo or Kerablend.
A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.
Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.
PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.
HMI-115: Frequently Asked Questions About Hair Loss TreatmentHMI-115 is an investigational anti-prolactin-receptor antibody being trialled for androgenetic alopecia. It is not approved anywhere; its hair-loss evidence is a 16-person Phase 1b announced only by press release, plus a completed 192-man Phase 2 in China whose results are not yet published.